^
Association details:
| Biomarker: | BCR-ABL1 fusion |
|---|---|
| Cancer: | B Acute Lymphoblastic Leukemia |
| Drug: | Tecartus (brexucabtagene autoleucel) (CD19-targeted CAR-T immunotherapy) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
12/16/2021
Excerpt:
PRINCIPLES OF SYSTEMIC THERAPY...PREGIMENS FOR RELAPSED Ph-POSITIVE B-ALL...Other Recommended Regimens...Brexucabtagene autoleucel
